Shares of Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) have been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $46.25.
A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus initiated coverage on shares of Tempus AI in a report on Tuesday, July 9th. They issued a “buy” rating and a $45.00 price target on the stock. William Blair started coverage on Tempus AI in a report on Tuesday, July 9th. They issued an “outperform” rating on the stock. Longbow Research assumed coverage on shares of Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $48.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $47.00 target price on shares of Tempus AI in a research note on Wednesday. Finally, Loop Capital initiated coverage on Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $48.00 target price for the company.
View Our Latest Report on Tempus AI
Hedge Funds Weigh In On Tempus AI
Tempus AI Trading Down 0.5 %
Shares of NASDAQ:TEM traded down $0.18 during midday trading on Friday, reaching $38.75. 336,632 shares of the company traded hands, compared to its average volume of 1,227,110. Tempus AI has a 12 month low of $22.89 and a 12 month high of $47.09.
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Articles
- Five stocks we like better than Tempus AI
- What is the Euro STOXX 50 Index?
- MarketBeat Week in Review – 8/5 – 8/9
- 3 Small Caps With Big Return Potential
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- 5 discounted opportunities for dividend growth investors
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.